New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

Injection 8 mg for treating macular edema caused by retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusions. The findings were presented at the virtual Angiogenesis, ...

The Windsor Library’s Central branch has to move from its current location earlier than anticipated. CTV Windsor’s Chris Campbell explains why. CTV News App Contact Us Newsletters Team ...

According to the company, the findings are consistent across various types of RVO, including central, branch, and hemiretinal vein occlusions. Through the 36 weeks, an 88% of the Eylea HD-treated ...

The QUASAR trial a global double-masked, active-controlled Phase 3 trial evaluating the efficacy and safety of EYLEA HD in patients with macular edema secondary to RVO, including those with central ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions. The data were ...